• IPO proceeds utilization: The ₹500 crore IPO includes a ₹125 crore fresh issue priced at ₹227 to ₹239 per share, with proceeds directed toward center capex (around ₹48 crore), marketing (₹10 crore), technology upgrades, and general corporate purposes.
• Network expansion roadmap: The company plans to open 319 centers over the next 30 to 36 months, focusing on deepening penetration into tier-2 and tier-3 cities beyond its existing footprint of 57 cities across 20 states.
• Earned revenue policy: Operating as a for-profit social enterprise on the main board, the company generates 100% of its revenue from clinical therapy sessions and consultations, completely barring donations and CSR funding.
• Therapy delivery model: Care for conditions such as autism, ADHD, and Down syndrome is conducted in 45-minute sessions structured primarily into tailor-made 12- or 24-session packages reassessed every three months, with per-session payment options for families in need.